Advertisement

 

 

Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma.

Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma.
Author Information (click to view)

Chiu YS, Hsing CH, Li CF, Lee CY, Hsu YH, Chang MS,


Chiu YS, Hsing CH, Li CF, Lee CY, Hsu YH, Chang MS, (click to view)

Chiu YS, Hsing CH, Li CF, Lee CY, Hsu YH, Chang MS,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Scientific reports 2017 12 147(1) 17609 doi 10.1038/s41598-017-17054-1
Abstract

Interleukin (IL)-20 is a proinflammatory cytokine involved in rheumatoid arthritis, atherosclerosis, and osteoporosis. However, the role of IL-20 in hepatocellular carcinoma (HCC) is unclear. We explored the function of IL-20 in HCC. Tumor tissue samples were analyzed the expression of IL-20 and cyclin D1 by using immunohistochemistry staining and quantitative real-time polymerase chain reaction (qRT-PCR) analysis. To examine the role of anti-IL-20 monoclonal antibody (7E) in tumor growth, BALB/c mice was injected with ML-1 cells and treated with 7E. HCC tumor tissue expressed higher levels of IL-20 than did non-tumor tissue. High IL-20 expression in HCC was correlated with poor overall survival (relative risk:>3). IL-20 and cyclin D1 expression were also highly correlated in HCC patient specimens and 3 human HCC cell lines. IL-20 also increased cell proliferation and migration, and it regulated matrix metalloproteinase (MMP)-13, tumor necrosis factor (TNF)-α, cyclin D1, and p21WAF1 expression in ML-1 cells. 7E attenuated tumor growth in mice inoculated with ML-1 cells. The expression of cyclin D1, TNF-α, MMP-9, and vascular endothelial growth factor was significantly inhibited after 7E treatment. The findings of this study suggest that IL-20 plays a role in the tumor progression of HCC.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen − 6 =

[ HIDE/SHOW ]